Indirect treatment comparison of idecabtagene vicleucel versus conventional care in triple-class exposed multiple myeloma.
Sign Up to like & getrecommendations! Published in 2022 at "Journal of comparative effectiveness research"
DOI: 10.2217/cer-2022-0045
Abstract: Aim: To compare the efficacy of idecabtagene vicleucel (ide-cel, bb2121) versus conventional care (CC) in triple-class exposed relapsed and refractory multiple myeloma (RRMM) patients. Patients & methods: A matching-adjusted indirect comparison was conducted using individual… read more here.
Keywords: care triple; versus conventional; idecabtagene vicleucel; triple class ... See more keywords
Practice patterns and outcomes for triple-class exposed patients with relapsed/refractory multiple myeloma in Japan.
Sign Up to like & getrecommendations! Published in 2022 at "Future oncology"
DOI: 10.2217/fon-2022-0846
Abstract: Aim: Treatment options for triple-class exposed (TCE) patients with multiple myeloma (MM) in Japan are limited. Materials & methods: Retrospective observational study using the Medical Data Vision database (April 2008-April 2021). Eligible adults with MM… read more here.
Keywords: triple class; myeloma japan; class exposed; treatment ... See more keywords
Elranatamab versus physician’s choice of treatment in patients with triple-class exposed/refractory multiple myeloma: an updated matching-adjusted indirect comparison
Sign Up to like & getrecommendations! Published in 2025 at "Journal of Comparative Effectiveness Research"
DOI: 10.57264/cer-2024-0236
Abstract: Aim: Despite the availability of novel treatment options for patients with triple-class exposed/refractory multiple myeloma , there is a lack of consensus on the optimal regimen. A previous unanchored matching-adjusted indirect comparison (MAIC) of the… read more here.
Keywords: exposed refractory; treatment; patients triple; triple class ... See more keywords